Testing markers to predict lung inflammation after lung cancer treatment
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study looks for early “predictive markers” to tell who is most likely to develop lung inflammation after standard treatment for non-small cell lung cancer. It may help clinicians spot problems sooner and tailor care, using additional monitoring during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed non-small cell lung cancer and are planning the same treatment sequence as the PACIFIC trial: chemo plus radiation, then immunotherapy (durvalumab).
- You can receive all treatment and study checkups at MD Anderson Cancer Center (MDACC).
- You have a smartphone that can send study data by Wi‑Fi or your own cellular plan.
- You can do home breathing testing (spirometry) once a week for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at blood and tissue biomarkers to predict how well immunotherapy (with or without chemotherapy) works for advanced non-small cell lung cancer. It also helps decide the best second treatment if the first one stops working.
This study looks for signs in the blood that can tell if a lung cancer patient is developing a side effect called pneumonitis (lung inflammation) from checkpoint inhibitor treatment. It may help doctors catch and treat this side effect early.
This study looks at using blood and imaging markers to predict if patients with lung cancer who receive both immunotherapy and chest radiation will develop lung inflammation (called radiation lung injury). It may help doctors personalise care and reduce side effects.
This study is looking at biomarkers (clues in your blood and tumor) to better understand how advanced lung cancer responds to immunotherapy. It aims to help doctors predict which treatments might work best for you in the future.
This study collects blood and sputum (phlegm) samples from people with lung cancer before and during immunotherapy. The goal is to see if certain immune markers in these samples can predict how well the treatment works.
This trial tests whether a blood test (ctDNA) can help predict how well a combination of chemotherapy and immunotherapy (and sometimes radiation) works before surgery for non-small cell lung cancer. It aims to see if the blood test can detect small amounts of remaining cancer to guide further treatment.
Hear when a new Lung Non-Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.